KRAS and familial pancreatic carcinoma: In our study, we found that either trametinib or JQ1 alone could inhibit the proliferation of some pancreatic cancer cell lines with KRAS alterations, irrespective of the mutational loci of KRAS and the mutational status of the other driver genes.